Guidance for Immunosuppression Risk Assessment

Co-chairs: Andrew Rooney
Susan Makris
RAF staff: Michael Broder

Office of the Science Advisor
Objectives

• Develop a framework for conducting risk assessments on immunological endpoints
• Inform risk assessors on the components and functions of the immune system
• Improve transparency and consistency of agency documents
Milestones

- 2004  Initiation of the project
- 2006  Review of draft guidance document
- 2007  “Nexus” workshop
- 2008  Revised draft to RAF
- 2008  Internal review
- 2009  External review
- 2010  Completion
Issues

- Biological vs. statistical significance
- Sensitive life stages/populations
- Gender differences
- Changes in humoral vs. cellular immunity
- Animal model data vs. epidemiological/clinical studies
Document Organization

1. Overview
2. Relationship between Immunosuppression and Adverse Effects
3. Problem Formulation
4. Hazard Characterization
5. Quantitative Dose-Response Analysis
6. Exposure Assessment
7. Risk Characterization
8. Appendix – Endpoints for Evaluating Systemic Immunosuppression in Humans and Test Species